Association of GLP ‐1 Receptor Agonist Use With Cardiovascular Outcomes and Mortality in Japanese Patients With Type 2 Diabetes: A Real‐World Claims Database Study
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.71209 ↗At a glance
Journal article in Diabetes, Obesity and Metabolism, 2026. Written by Masaya Koshizaka and 7 co-authors. Institution: Department of Nutrition and Metabolic Medicine, Center for Preventive Medical Sciences, Chiba University, Chiba, Japan. Major MEDLINE topics: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Cardiovascular Diseases, Hypoglycemic Agents. 16 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Japan Agency for Medical Research and Development (AMED) and Cross-ministerial Strategic Innovation Promotion Program (SIP), Ministry of Health, Labour and Welfare, Japan, The Takeda Science Foundation.
Topics: Diabetes mellitus
Abstract (original language)
Aims
Large‐scale clinical trials have shown multiple effects of glucagon‐like peptide 1 receptor agonists (GLP‐1RAs); however, similar evidence for Asian patients is limited. Therefore, using a Japanese large‐scale claims‐based database, the effects of GLP‐1RAs on cardiovascular and cerebrovascular events including mortality were compared with those of other glucose‐lowering agents. Materials and Methods Patients with type 2 diabetes (T2D) were identified from a claims database of approximately 1.9 million individuals. Those newly prescribed GLP‐1RAs between 2014 and 2021 were assigned to the GLP‐1RA group, while those initiating other glucose‐lowering agents served as controls. The primary outcome was cardiovascular or cerebrovascular events or all‐cause mortality. Logistic regression analysis was performed using explanatory variables, and nearest‐neighbour propensity score matching was performed between the groups. The period from the initiation of new medication to event occurrence was calculated and analysed using the Cox proportional hazards model, with a maximum follow‐up of 38 months.
Results
Among 469 461 eligible patients, 2401 received GLP‐1RAs and 53 946 were controls. After propensity matching, 2147 patients remained in each group. The median follow‐up was 12 months. No significant difference was observed in 3‐point major adverse cardiovascular events (3‐point MACE) (GLP‐1RA, 7.08% ( n = 152) versus control, 8.20% ( n = 176); hazard ratio (HR), 0.920; 95% confidence interval (CI) 0.740–1.143, p = 0.450). However, all‐cause mortality was lower in the GLP‐1RAs group (5.36% ( n = 115) versus 7.36% ( n = 158), HR 0.776, 95% CI 0.610–0.987, p = 0.039).
Conclusions
GLP‐1RA showed no association with 3‐point MACE difference but showed lower all‐cause mortality. These findings possibly reflect residual confounding.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Nutrition and Metabolic Medicine, Center for Preventive Medical Sciences, Chiba University, Chiba, Japan.
- Department of Endocrinology and Gerontology, Chiba University Graduate School of Medicine, Chiba, Japan.
- Department of Medicine, Division of Diabetes, Metabolism and Endocrinology, Chiba University Hospital, Chiba, Japan.
- Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Kimitsu Chuo Hospital, Chiba, Japan.
- Institute for Health Economics and Policy, Tokyo, Japan.
- Institute of Industrial Science, The University of Tokyo, Tokyo, Japan.
ORCID profiles: Masaya Koshizaka, Ryoichi Ishibashi, Tomoki Ishikawa, Koutaro Yokote
Funding
- Japan Agency for Medical Research and Development (AMED) and Cross-ministerial Strategic Innovation Promotion Program (SIP)
- Ministry of Health, Labour and Welfare, Japan
- The Takeda Science Foundation
- Japan Agency for Medical Research and Development
- Ministry of Health, Labour and Welfare
Cite
APA
Koshizaka, M., Ishibashi, R., Ishikawa, T., Goda, K., Sato, J., Kitsuregawa, M., Yokote, K., & Mitsutake, N. (2026). Association of GLP ‐1 Receptor Agonist Use With Cardiovascular Outcomes and Mortality in Japanese Patients With Type 2 Diabetes: A Real‐World Claims Database Study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71209
Vancouver
Koshizaka M, Ishibashi R, Ishikawa T, Goda K, Sato J, Kitsuregawa M, et al. Association of GLP ‐1 Receptor Agonist Use With Cardiovascular Outcomes and Mortality in Japanese Patients With Type 2 Diabetes: A Real‐World Claims Database Study. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71209
BibTeX
@article{Koshizaka2026,
author = {Koshizaka, Masaya and Ishibashi, Ryoichi and Ishikawa, Tomoki and Goda, Kazuo and Sato, Jumpei and Kitsuregawa, Masaru and Yokote, Koutaro and Mitsutake, Naohiro},
title = {Association of GLP ‐1 Receptor Agonist Use With Cardiovascular Outcomes and Mortality in Japanese Patients With Type 2 Diabetes: A Real‐World Claims Database Study},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.71209}
}
EUVIMED